ABUS - Moderna Investors Should Beware Patent-Dispute Fallout

2024-04-23 14:40:54 ET

Summary

• Moderna's stock rose after positive results from its cancer vaccine trial, but legal issues could lead to a massive judgment against the company.
• Moderna is facing a patent dispute over its use of lipid nanoparticles technology without proper licensing or compensation.
• I believe the company's defense, citing an obscure law, is unlikely to hold up in court, and the outcome could result in significant damages.

Shares in Moderna ( MRNA ), maker of the breakthrough mRNA shot against Covid-19, jumped to a three-month high this month [April 2024] after its cancer vaccine showed promising results in an early-stage clinical trial for patients with head and neck cancer. [1] ...

For further details see: